ALK and non-small cell lung carcinoma: Pemetrexed-based chemotherapy is effective in patients with ALK-rearranged NSCLC who were treatment naive and previously treated, and it has been the optimal treatment for patients who experienced disease progression while on second-generation ALK TKIs.1